Johnson & Johnson Inc is set to pay up to $1 billion to acquire privately-held Aragon Pharmaceuticals Inc of the US which has a product in Phase 2 development for castration resistant prostate cancer. The upfront payment is $650 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
